FDA Advisors Slam Lipocine’s Testosterone Pill, Raising Doubts About ‘Low T’ Drugs

Investors are fleeing from testosterone drugmaker Lipocine today, but its FDA woes portend bigger challenges for companies developing new versions of the embattled hormone.January 11, 2018 at 11:52AM

via Forbes Real Time http://ift.tt/2mlv6TM

Author: edaccessible

I am a brain aneurysm survivor. Thankful for every day. Devoted father and husband. Passionate about new technologies; in particular anything to do with accessibility and universal design.